Udenafil: Efficacy and tolerability in the management of erectile dysfunction

Sung gu Kang, je Jong Kim

    Research output: Contribution to journalReview articlepeer-review

    13 Citations (Scopus)


    Udenafil is a potent novel phosphodiesterase-5 inhibitor approved for use in Korea. Udenafil has unique properties, with a Tmax of 1.0–1.5 h and a T1/2 of 11–13 h (a relatively rapid onset and a long duration of action). Therefore, both on-demand and once-daily use of udenafil have been reported. Udenafil's efficacy and tolerability have been evaluated in several studies, and recent and continuing studies have demonstrated udenafil's promise in both dosing regimens. Presently, tadalafil is the only FDA-approved drug for daily dosing, but udenafil can be used as a once-daily dose for erectile dysfunction patients who cannot tolerate tadalafil due to phosphodiesterase subtype selectivity. Udenafil as an on-demand or once-daily dose is effective and tolerable, but more studies are needed in patients of other ethnicities and with comorbid conditions such as diabetes mellitus, hypertension, and benign prostate hyperplasia.

    Original languageEnglish
    Pages (from-to)101-110
    Number of pages10
    JournalTherapeutic Advances in Urology
    Issue number2
    Publication statusPublished - 2013 Apr


    • Erectile dysfuction
    • Once-daily dosing
    • Phosphodiesterase type 5
    • Udenafil

    ASJC Scopus subject areas

    • Urology


    Dive into the research topics of 'Udenafil: Efficacy and tolerability in the management of erectile dysfunction'. Together they form a unique fingerprint.

    Cite this